Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
24 studies found for:    Open Studies | "Sweat"
Show Display Options
Rank Status Study
21 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
22 Not yet recruiting Prosthetic Socket Interface Design on Socket Comfort, Residual Limb Health, and Function for the Transfemoral Amputee
Condition: Amputation
Interventions: Device: Ischial Ramus Containment (IRC);   Device: Dynamic Socket Ischial Ramus Containment (IRC);   Device: Sub-Ischial Interface (Sub-I)
23 Recruiting ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor
Condition: Cystic Fibrosis
Intervention: Drug: Lumacaftor plus Ivacaftor
24 Recruiting Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Condition: Cystic Fibrosis
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-24) Next Page   
Study has passed its completion date and status has not been verified in more than two years.